Biology subjects

Rioux, V.

Publications and source records attributed to Rioux, V..

3 recordsLinked to original sources

bioRxiv2025

Modulation of SLP-2 expression protects against alpha-synuclein neuropathology by mitigating mitochondrial dysfunction

Parkinsons Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss and the accumulation of alpha-synuclein (Syn)-rich aggregates known as Lewy bodies. Mitochondrial dysfunction is a key contributor to PD pathology, and mitochondrial defects are part of the pathogenic mechanisms induced by Syn. Stomatin-Like protein 2 (SLP-2) is a mitochondrial scaffold protein that regulates mitochondrial integrity and function. Here, we investigated whether SLP-2 induction can counteract Syn-induced mitochondrial dysfunction and neurodegeneration. We found that SLP-2 levels were reduced in human PD brains and an A53T Syn mouse model. Mild overexpression of SLP-2 improved mitochondrial function, reduced oxidative stress, and prevented Syn-mitochondria interactions in human iPSC-derived neurons. In vivo, SLP-2 overexpression protected dopaminergic neurons and motor function, while its depletion exacerbated degeneration and motor deficits in both mouse and Drosophila models. These findings suggest SLP-2 as a key regulator of mitochondrial resilience and a potential therapeutic target for PD and alpha-synucleinopathies.

neuroscience↗

bioRxiv2024

Fatty acid-mediated induction of CYP2E1 activity in HepaRG cells is not systematically associated with exacerbated acetaminophen cytotoxicity

Hepatic cytochrome P450 2E1 (CYP2E1) is thought to contribute to the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as non-alcoholic fatty liver disease (NAFLD). Indeed, increased activity of CYP2E1 in obese subjects with fatty liver may contribute to higher oxidative stress, mitochondrial dysfunction and the progression to steatohepatitis. Besides, higher CYP2E1 activity in obesity and MASLD is deemed to increase the risk of acetaminophen (APAP)-induced hepatotoxicity because this pain reliever is metabolized by CYP2E1 to N-acetyl-p-benzoquinone imine (NAPQI), a highly toxic metabolite. Although the mechanism of MASLD-associated CYP2E1 induction is still unclear, evidence suggests that hepatic CYP2E1 activity is regulated by fatty acids (FAs). In this study, we investigated the effect of 9 FAs differing by their carbon chain length and their degree of unsaturation on CYP2E1 activity in differentiated HepaRG cells. One-week incubation with palmitic acid (PA), stearic acid (SA) and linoleic acid (LA) induced CYP2E1 activity but only LA exposure induced triglyceride accumulation. APAP hepatotoxicity was then assessed in HepaRG cells cultured with or without PA, SA or LA. Acute APAP cytotoxicity was exacerbated in presence of PA or SA and this was accompanied by more severe mitochondrial dysfunction. These effects were not observed when cells were incubated with LA. Hence, FA-mediated increased CYP2E1 activity in HepaRG cells does not necessarily require steatosis. In addition, FA-mediated CYP2E1 induction does not systematically lead to higher APAP-induced cytotoxicity. By favoring triglyceride accumulation, LA might curb APAP-induced mitochondrial dysfunction and cell death.

pharmacology and toxicology↗

bioRxiv2024

PPARgamma, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas

Human hepatocellular carcinomas (HCCs) with cancer stem cell (CSC) features are a subclass of therapeutically challenging cancers. We recently showed that retrodifferentiation of hepatic cancer cells into CSC-like cells leads to metabolic reprogramming and chemoresistance. The molecular mechanisms whereby differentiated cancer cells switch towards a CSC phenotype are poorly understood. By studying metabolic reprogramming associated with HCC cell plasticity, we identified an unsuspected role of peroxisome proliferator-activated receptor (PPAR){gamma} in hepatic CSC phenotype acquisition. Gene expression and metabolic analyses performed throughout cell differentiation/retrodifferentiation process of human HepaRG and HBG-BC2 HCC cells show that metabolic reprogramming in hepatic CSCs is associated with fragmented mitochondrial network, decreased respiration, de novo lipogenesis, fatty acid oxidation, but increased glycolysis and lipid storage. Mitochondrial genes downregulated in HepaRG-CSCs are also downregulated in the STEM HCC subclass. While PPAR is the main isoform in differentiated hepatic cells, we find high PPAR{gamma} expression in hepatic CSCs. Accordingly, nuclear localization of PPAR{gamma} is detected in human HCC tumors and PPAR{gamma}high/PPARlow expression is associated with the STEM HCC subclass and a poor outcome in human HCC cohorts. PPAR{gamma} silencing or/and inhibition of its target gene pyruvate dehydrogenase kinase 4 reactivates cell respiration, increases reactive oxygen species production and sensitizes hepatic CSCs to chemotherapy. Conversely, PPAR activation synergizes with chemotherapy to induce cell death. Targeting PPAR{gamma}, a key regulator of metabolic reprogramming and stemness in hepatic CSCs, or modulating the PPAR{gamma}/PPAR balance that finely tunes the differentiation/retrodifferentiation process in HCC deserves further investigation for antitumor therapy. Implications heading and statementPPAR{gamma}, a key regulator of metabolic reprogramming and stemness in hepatic CSC, reduces oxidative phosphorylation and reactive oxygen species production, therefore contributing to HCC chemoresistance.

cancer biology↗